The dose printed on the box is a promise. Bioavailability is the part of that promise the body actually keeps — and for a great many oral medicines, the gap between the two is enormous.
What bioavailability really means
Bioavailability is the fraction of a dose that reaches the bloodstream in a form the body can use. Injected straight into a vein, a drug is fully bioavailable by definition. Swallowed, the same drug must survive the stomach, dissolve, cross the gut wall and pass through the liver before any of it reaches the circulation. Every one of those steps takes a cut.
For many oral drugs, most of the dose never arrives. The label counts what you swallow, not what works.
Where the dose actually goes
Three bottlenecks account for most of the loss. A drug that will not dissolve cannot be absorbed — and a large share of the molecules in today’s development pipeline are poorly soluble. A drug that dissolves but cannot permeate the gut wall is carried away unused. And a drug that does cross the wall still meets first-pass metabolism in the liver, which can break down much of it before it ever circulates.
The result is a system that is busy for very little return: a tablet that must be manufactured, swallowed and processed in full, so that a fraction of it can do the work.
Why it is the quiet problem in medicine
Poor bioavailability is usually filed under clinical pharmacology — a number for dosing and labels. It is far more than that. Low absorption forces higher doses, which means more active ingredient to synthesise, more variation between patients, and more of every batch lost as waste. The clearest modern example is oral semaglutide, absorbed at roughly one per cent: to match the effect of a weekly injection, a daily tablet has to carry many times more drug substance.
Bioavailability is not only a clinical number. It is one of the largest unpriced levers on the cost of making a medicine.
It is a design choice, not a law of nature
The tablet treats poor absorption as unavoidable: dissolve first, absorb second, lose most of it in between. But the bottleneck sits largely in the dosage form, not the molecule. Design for absorption from the start — rather than compression and dissolution — and the arithmetic changes.
Read deeper
- Bioavailability Is Pharma’s Dirty Secret — why a 100 mg tablet rarely delivers 100 mg of effect.
- The 80% Problem: Why Most of Every Dose Is Wasted — the scale of the loss, in plain numbers.
- Absorption Is the Real Battlefield — why absorption, not the molecule, decides the outcome.
- The Dissolution Trap — how the dissolve-then-absorb model paces and limits every dose.
- Why Ibuprofen Works Better Than It Should — a familiar drug, read through the lens of delivery.
About Ibumix
Ibumix is developing a series of new liquid drug-delivery platforms built on glyceryl caprate (GCC) lipid chemistry — re-engineering how established medicines are delivered, beginning with the NSAID class. Ibuprofen and naproxen are the starting points; the opportunity extends well beyond them.
Sources
- Definition and determinants of oral bioavailability (dissolution, permeability, first-pass metabolism) — pharmacology and pharmaceutics literature (e.g. Aulton’s Pharmaceutics; BCS framework).
- Oral semaglutide absolute bioavailability ~0.4–1% — approved prescribing information for oral semaglutide (Rybelsus) and published population-PK analyses.
- A large proportion of development-stage molecules are poorly water-soluble (BCS Class II/IV) — formulation-science literature.
See how this connects to what Ibumix is building: the Mix platform — one architecture, seven chassis.